Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR6390 + omeprazole
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
SHR6390 + omeprazole is a combination of two drugs. SHR6390 is an investigational small molecule cyclin-dependent kinase 4/6 (CDK4/6) inhibitor developed for the treatment of certain cancers, notably hormone receptor-positive, HER2-negative breast cancer. Omeprazole is a well-established proton pump inhibitor (PPI) that decreases gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells. Omeprazole is used to treat conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome[1][2][3][6]. The combination may be studied or used in clinical settings where both cancer therapy and management of gastrointestinal symptoms are required.
- Brand names
- PrilosecLosecZegeridFIRST OmeprazolePriLOSEC OTC
- Other names
- none
02
Targets
ATP1A1 (Sodium/potassium-transporting ATPase subunit alpha-1)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on SHR6390 + omeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR6390 + omeprazole.